Sign up to all DiabetesontheNet journals
Journals
Sign up to all DiabetesontheNet journals
By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.
Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.
We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.
Journal of
Diabetes Nursing
Issue:
Early View
GLP-1 agonists and the potential risk of pulmonary aspiration during surgery
The Medicines and Healthcare products Regulatory Agency (MHRA) has released a drug safety update. It alerts healthcare professionals (HCPs) to the potential risk of pulmonary aspiration in people using GLP-1 or dual GIP/GLP-1 receptor agonists (RAs) who undergo surgery or procedures with general anaesthesia or deep sedation.
The GLP-1 and dual GIP/GLP-1 RAs available in the UK include dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide. Tirzepatide is a GLP-1 RA combined with a GIP RA.
In the update, HCPs are reminded that one of the effects of GLP-1 and GIP/GLP-1 RAs is to cause delayed gastric emptying. This may increase the risk of residual gastric contents despite preoperative fasting. Individuals with underlying diabetic gastroparesis, as well as other comorbidities such as obesity or gastroesophageal reflux disease, and symptoms of delayed gastric emptying (such as nausea, vomiting and abdominal pain) may be at higher risk of aspiration.
HCPs should also consider that individuals may have bought these medications for aesthetic weight loss and may not disclose this unless asked directly. They should also be aware that private prescriptions are not always included in medical notes or drug history.
The update also contains advice for HCPs to provide to patients who are taking a GLP-1 or GIP/GLP-1 RA. This includes informing their healthcare team, including the anaesthetist, about this prior to surgery as a modification to the pre-procedure instruction and anaesthetic technique may be required. Prescribed medicines should be taken as usual and not stopped without first discussing it.
The MHRA’s drug safety update can be read here.
Insulin management: Treatment choices and pregnancy
Diabetes UK releases vision for diabetes care
The role of the youth worker in improving outcomes in young people living with type 1 diabetes
Latest news: tirzepatide prescribing for obesity, AI predicting kidney disease, and recognition of type 5 diabetes
Tirzepatide roll out for obesity clearer, but questions remain
Malnutrition-related diabetes formally recognised after years of debate
What’s hot in diabetes nursing? April 2025
Case study outlining the complexities of managing glycaemia in a pregnant woman with type 1 diabetes.
30 May 2025
Charity publishes its 10-year vision to transform diabetes prevention, care and treatment.
22 May 2025
Improving the experience of young people preparing to transition to adult services.
21 May 2025
Developments that will impact your practice.
7 May 2025